Clinical trial
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in Patients With Relapsed Advanced Malignancies( BHARAT-1)
NCT05607199 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in Patients With Relapsed Advanced Malignancies( BHARAT-1)
- Lead sponsor
- Aurigene Discovery Technologies Limited
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- September 16, 2022
- Completion date
- November 27, 2024
- Enrollment
- 27 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia, myelodysplastic syndromes, non hodgkin lymphoma, solid tumor, adult